JP2025503188A - 腫瘍溶解性ウイルス及びその用途 - Google Patents

腫瘍溶解性ウイルス及びその用途 Download PDF

Info

Publication number
JP2025503188A
JP2025503188A JP2024544471A JP2024544471A JP2025503188A JP 2025503188 A JP2025503188 A JP 2025503188A JP 2024544471 A JP2024544471 A JP 2024544471A JP 2024544471 A JP2024544471 A JP 2024544471A JP 2025503188 A JP2025503188 A JP 2025503188A
Authority
JP
Japan
Prior art keywords
amino acid
protein
acid substitutions
oncolytic virus
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503188A5 (enExample
Inventor
周国慶
張凡
馬良
田▲ティン▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joint Biosciences SH Ltd
Original Assignee
Joint Biosciences SH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Biosciences SH Ltd filed Critical Joint Biosciences SH Ltd
Publication of JP2025503188A publication Critical patent/JP2025503188A/ja
Publication of JP2025503188A5 publication Critical patent/JP2025503188A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2024544471A 2022-01-26 2023-01-09 腫瘍溶解性ウイルス及びその用途 Pending JP2025503188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210094869.1 2022-01-26
CN202210094869.1A CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
PCT/CN2023/071375 WO2023143023A1 (zh) 2022-01-26 2023-01-09 溶瘤病毒及其应用

Publications (2)

Publication Number Publication Date
JP2025503188A true JP2025503188A (ja) 2025-01-30
JP2025503188A5 JP2025503188A5 (enExample) 2026-01-08

Family

ID=81673943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544471A Pending JP2025503188A (ja) 2022-01-26 2023-01-09 腫瘍溶解性ウイルス及びその用途

Country Status (8)

Country Link
US (1) US20240424040A1 (enExample)
EP (1) EP4471132A4 (enExample)
JP (1) JP2025503188A (enExample)
KR (1) KR20240137069A (enExample)
CN (6) CN119709650A (enExample)
AU (1) AU2023210771A1 (enExample)
CA (1) CA3243385A1 (enExample)
WO (1) WO2023143023A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119709650A (zh) * 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用
CN116350759A (zh) * 2023-03-30 2023-06-30 上海荣瑞医药科技有限公司 溶瘤病毒疫苗和免疫细胞联合治疗肿瘤的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1769433A (zh) * 2004-11-04 2006-05-10 张庆勇 重组水疱性口炎病毒及其应用
JP2012504944A (ja) * 2008-10-08 2012-03-01 ラーアー，ドロテー・フォン 腫瘍の療法のためのｌｃｍｖ−ｇｐシュードタイプ化ｖｓｖベクターおよび腫瘍浸潤性ウイルス産生細胞
CN105087645A (zh) * 2015-08-04 2015-11-25 上海交通大学 M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用
CN110305198A (zh) * 2018-03-27 2019-10-08 苏州奥特铭医药科技有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN110819657A (zh) * 2018-08-10 2020-02-21 苏州奥特铭医药科技有限公司 一种减毒棒状病毒的制备方法及应用
WO2021228106A1 (zh) * 2020-05-12 2021-11-18 上海荣瑞医药科技有限公司 溶瘤病毒与免疫检查点抑制剂联合治疗肿瘤
WO2021228105A1 (zh) * 2020-05-12 2021-11-18 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010124788A (ru) * 2007-12-21 2012-01-27 Ваейт ЭлЭлСи (US) Генетически модифицированный ослабленный вирус везикулярного стоматита, композиции и способы их применения
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
EP3246410A1 (en) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
TWI894135B (zh) * 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
CN119709650A (zh) * 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1769433A (zh) * 2004-11-04 2006-05-10 张庆勇 重组水疱性口炎病毒及其应用
JP2012504944A (ja) * 2008-10-08 2012-03-01 ラーアー，ドロテー・フォン 腫瘍の療法のためのｌｃｍｖ−ｇｐシュードタイプ化ｖｓｖベクターおよび腫瘍浸潤性ウイルス産生細胞
CN105087645A (zh) * 2015-08-04 2015-11-25 上海交通大学 M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用
CN110305198A (zh) * 2018-03-27 2019-10-08 苏州奥特铭医药科技有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN110819657A (zh) * 2018-08-10 2020-02-21 苏州奥特铭医药科技有限公司 一种减毒棒状病毒的制备方法及应用
WO2021228106A1 (zh) * 2020-05-12 2021-11-18 上海荣瑞医药科技有限公司 溶瘤病毒与免疫检查点抑制剂联合治疗肿瘤
WO2021228105A1 (zh) * 2020-05-12 2021-11-18 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GYOUNG NYOUN KIM ET AL.: ""Creation of Matrix Protein Gene Variants of Two Serotypes of Vesicular Stomatitis Virus as Prime-B", JOURNAL OF VIROLOGY, vol. 89, no. 12, JPN6025038877, 15 June 2015 (2015-06-15), pages 6338 - 6351, ISSN: 0005808726 *
HIMANGI R. JAYAKAR ET AL.: ""Identification of Two Additional Translation Products from the Matrix (M) Gene That Contribute to", JOURNAL OF VIROLOGY, vol. 76, no. 16, JPN6025038876, 15 August 2002 (2002-08-15), pages 8011 - 8018, ISSN: 0005808727 *

Also Published As

Publication number Publication date
CN119709650A (zh) 2025-03-28
US20240424040A1 (en) 2024-12-26
CN119709652A (zh) 2025-03-28
CN114540316B (zh) 2025-01-03
CN119709651A (zh) 2025-03-28
AU2023210771A1 (en) 2024-08-15
CN119736261A (zh) 2025-04-01
CA3243385A1 (en) 2025-06-17
KR20240137069A (ko) 2024-09-19
CN119709649A (zh) 2025-03-28
EP4471132A4 (en) 2026-02-25
EP4471132A1 (en) 2024-12-04
WO2023143023A1 (zh) 2023-08-03
CN114540316A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
US20230190838A1 (en) Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors
JP2025503188A (ja) 腫瘍溶解性ウイルス及びその用途
JP2025503188A5 (enExample)
AU2018303064B2 (en) Virus for treating tumors
AU2019254948B2 (en) Coxsackie virus B for treating tumors
JP2025523073A (ja) 組み換え腫瘍溶解性ウイルス及びその用途
AU2018320550B2 (en) Echovirus for treating tumor
US20240226209A1 (en) Oncolytic virus and use thereof
HK40105653A (en) Oncolytic virus and use thereof
CA3070628C (en) Enterovirus d68 (ev-d68) for treatment of tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303